PDS Biotechnology Corp
corporate_fare Company Profile
PDS Biotechnology Corp (NASDAQ:PDSB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 33 items for PDSB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-22, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PDSB spans 8-K, SCHEDULE 13D, 10-Q, S-3.
Recent high-impact activity:
- PDS Biotech Publishes VERSATILE-002 Phase 2 Data in JAMA Oncology: 39.3-Month Median OS in HPV16+ Head and Neck Cancer
- PDS0101 Phase 2 Data in JAMA Oncology Shows 39.3-Month Survival in Head and Neck Cancer
- Nant Capital Discloses 19.9% Stake in PDS Biotech with $10M Milestone Tranche and PDS0101 License Option
- PDS Biotech Closes $11.3M Initial Tranche of Nant-Led PIPE, Redeems Yorkville Note
- PDS Biotech Secures $22.55M PIPE Led by Dr. Patrick Soon-Shiong, Gains Board Seats and PDS0101 Option
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 6,406,521 shares in PDSB as of the September 15, 2026 settlement, a 172.7% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 46.2% of PDSB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for PDSB, detected from its recent SEC filings · based on capital-structure filings through 2026-07-21.
$50 Million At-The-Market (ATM) Offering Activated · Significant Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →